Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects ...

Takeda rolls toward EU approval with its heir to Velcade

Damian Garde Takeda's top oncology prospect is moving toward approval in the European Union, as continental regulators have accepted the company's application and promised a ...

Raptor buys into cystic fibrosis with a $418M deal

Damian Garde Rare disease biotech Raptor Pharmaceutical signed a deal to pay up to $ 418 million to Tripex Pharmaceuticals in exchange for an inhaled treatment for cystic fibrosis. FierceBiotech ...

Ackman’s Valeant ties pay off yet again with Sprout buy

Carly Helfand Bill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan. ...

A biotech startup grows out of GlaxoSmithKline’s discarded NC R&D

Damian Garde GlaxoSmithKline is laying off nearly 1,000 employees in North Carolina in an effort to trim its R&D costs, cutting deep into the biotech ecosystem in Research Triangle ...

Amgen wraps up Aranesp, Enbrel marketing probe with $71M state-level settlement

Carly Helfand Amgen is paying up to resolve claims that it broke the rules while marketing anemia drug Aranesp and anti-inflammatory blockbuster Enbrel. The company has settled with ...

Troubled Lundbeck targets 1,000 layoffs in HQ, commercial revamp

Tracy Staton Lundbeck is going on a cost-cutting binge. Amid falling sales–and a few months after a new CEO took the helm–the Danish drugmaker says it will cut loose ...

AbbVie hands United a record $350M payoff for a speedy FDA review voucher

John Carroll The cost of a priority review voucher for the FDA keeps going up. AbbVie is forking over a record $ 350 million to acquire a voucher from United Therapeutics, giving them ...

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Carly Helfand Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers–including Evercore ISI analyst Umer Raffat, who ...

FDA clears a controversial female libido drug despite ‘modest’ effects and dangerous risks

Damian Garde The FDA cleared Sprout Pharmaceuticals' much-scrutinized flibanserin, a first-of-its-kind pill designed to boost women's sexual desire, but not without sticking ...

Gene therapy stalwart ReGenX plots a $100M IPO to strike out on its own

Damian Garde After years of outlicensing its gene therapy technology, ReGenX Bio is pressing forward with treatments of its own, filing to raise $ 100 million in an IPO to fund ...

Will docs jump on new biosims? Survey shows they’ll need some nudging

Carly Helfand Drugmakers are well aware of the biosimilars threatening to steal sales and market share from some of the world's best-selling biologics. Doctors, though? Not so much, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS